Search Results

You are looking at 11 - 16 of 16 items for :

  • "SGLT2 inhibitors" x
Clear All
Run-Qing Xiong Department of Ultrasonic Imaging, Xiamen Medical College Affiliated Second Hospital, Fujian, China

Search for other papers by Run-Qing Xiong in
Google Scholar
PubMed
Close
,
Yan-Ping Li Key Laboratory of Functional and Clinical Translational Medicine, Fujian Province University, Xiamen Medical College, Fujian, China

Search for other papers by Yan-Ping Li in
Google Scholar
PubMed
Close
,
Lu-Ping Lin Department of Endocrinology, Xiamen Medical College Affiliated Second Hospital, Fujian, China

Search for other papers by Lu-Ping Lin in
Google Scholar
PubMed
Close
, and
Jeng-Yuan Yao Key Laboratory of Functional and Clinical Translational Medicine, Fujian Province University, Xiamen Medical College, Fujian, China

Search for other papers by Jeng-Yuan Yao in
Google Scholar
PubMed
Close

potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy . Frontiers in Cardiovascular Medicine 2022 9 999254 . ( https://doi.org/10.3389/fcvm.2022.999254 ) 21 Peng M Xia T Zhong Y Zhao M Yue Y Liang L Zhong

Open access
David Koeckerling Medical Sciences Division, University of Oxford, Oxford, UK

Search for other papers by David Koeckerling in
Google Scholar
PubMed
Close
,
Jeremy W Tomlinson Oxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, Oxford, UK

Search for other papers by Jeremy W Tomlinson in
Google Scholar
PubMed
Close
, and
Jeremy F Cobbold Oxford Liver Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK

Search for other papers by Jeremy F Cobbold in
Google Scholar
PubMed
Close

reduction and cardiovascular event incidence ( 91 , 92 ). The safety and efficacy of semaglutide in NAFLD is being investigated in phase II clinical trials. Sodium-glucose transport protein-2 (SGLT-2) inhibitors impede renal glucose reabsorption, serving

Open access
Chunliang Yang Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
The Center for Biomedical Research, Tongji Hospital Research Building, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Search for other papers by Chunliang Yang in
Google Scholar
PubMed
Close
,
Junyi Li Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Search for other papers by Junyi Li in
Google Scholar
PubMed
Close
,
Fei Sun The Center for Biomedical Research, Tongji Hospital Research Building, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Search for other papers by Fei Sun in
Google Scholar
PubMed
Close
,
Haifeng Zhou Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Search for other papers by Haifeng Zhou in
Google Scholar
PubMed
Close
,
Jia Yang Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Search for other papers by Jia Yang in
Google Scholar
PubMed
Close
, and
Chao Yang Department of Gerontology, Hubei Provincial Hospital of Integrated Chinese and Western Medicine, Wuhan, China

Search for other papers by Chao Yang in
Google Scholar
PubMed
Close

enteral glucose absorption (alpha-glucosidase inhibitors) and increasing renal glucose excretion (SGLT-2 inhibitors). When mono-drug therapy fails, various combinations of drug administration are required for different clinical conditions. In worsened

Open access
Aldo Bonaventura Department of Internal Medicine, Division of Cardiology, Division of Laboratory Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Search for other papers by Aldo Bonaventura in
Google Scholar
PubMed
Close
,
Fabrizio Montecucco Department of Internal Medicine, Division of Cardiology, Division of Laboratory Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Department of Internal Medicine, Division of Cardiology, Division of Laboratory Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Department of Internal Medicine, Division of Cardiology, Division of Laboratory Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Search for other papers by Fabrizio Montecucco in
Google Scholar
PubMed
Close
, and
Franco Dallegri Department of Internal Medicine, Division of Cardiology, Division of Laboratory Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Search for other papers by Franco Dallegri in
Google Scholar
PubMed
Close

hypoglycemia (31% lower) (76) . The frequency of hypoglycemia with new GLDs, such as incretins and SGLT2 inhibitors, is very low (77) . Results of some trials indicated the efficacy of dipeptidyl peptidase (DPP)-4 inhibitors in improving glycemic control

Open access
Peter Wolf Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

Search for other papers by Peter Wolf in
Google Scholar
PubMed
Close
,
Yvonne Winhofer Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

Search for other papers by Yvonne Winhofer in
Google Scholar
PubMed
Close
,
Martin Krššák Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
High Field MR Centre, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria

Search for other papers by Martin Krššák in
Google Scholar
PubMed
Close
, and
Michael Krebs Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

Search for other papers by Michael Krebs in
Google Scholar
PubMed
Close

. Another question to be addressed in the future is if novel drug approaches for metabolic diseases, such as sodium-glucose-transporter-2 (SGLT-2) inhibitors or glucagon-like-peptide-1 (GLP-1) analogs that improve cardiovascular outcome in patients suffering

Open access
Iben Rix Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Zealand Pharma A/S, Søborg, Denmark

Search for other papers by Iben Rix in
Google Scholar
PubMed
Close
,
Marie L Johansen Department of Medicine, Herlev Hospital, University of Copenhagen, Herlev, Denmark

Search for other papers by Marie L Johansen in
Google Scholar
PubMed
Close
,
Asger Lund Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark

Search for other papers by Asger Lund in
Google Scholar
PubMed
Close
,
Malte P Suppli Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark

Search for other papers by Malte P Suppli in
Google Scholar
PubMed
Close
,
Elizaveta Chabanova Department of Radiology, Herlev Hospital, University of Copenhagen, Herlev, Denmark

Search for other papers by Elizaveta Chabanova in
Google Scholar
PubMed
Close
,
Gerrit van Hall Clinical Metabolomics Core Facility, Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Gerrit van Hall in
Google Scholar
PubMed
Close
,
Jens J Holst Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Jens J Holst in
Google Scholar
PubMed
Close
,
Nicolai J Wewer Albrechtsen Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Nicolai J Wewer Albrechtsen in
Google Scholar
PubMed
Close
,
Caroline Kistorp Department of Endocrinology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Caroline Kistorp in
Google Scholar
PubMed
Close
, and
Filip K Knop Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Steno Diabetes Center Copenhagen, Herlev, Denmark

Search for other papers by Filip K Knop in
Google Scholar
PubMed
Close

(2597–3021) 0.91 Diabetes medication, n (%)  Metformin 91 (82.7%) 46 (79.3%) 45 (86.5%) 0.32  SGLT-2 inhibitor 18 (16.4%) 7 (12.1%) 11 (21.2%) 0.20  Sulphonylurea 11 (10.0%) 4 (6.9%) 7 (13.5%) 0

Open access